KB408

Gene therapy / editing

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Alpha-1 Antitrypsin Deficiency

Competitive landscape

This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
KB408: this drugPhase 1Gene therapy / editingSERPINA1 (alpha-1 antitrypsin; gene replacement)not yet gradedNo reviewed efficacy summary in this indication
FazirsiranPhase 3RNA / oligonucleotideSERPINA1not yet gradedNo reviewed efficacy summary in this indication
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
BEAM-302Phase 1/2Gene therapy / editingSERPINA1 PiZ mutation (E342K)not yet gradedNo reviewed efficacy summary in this indication
TSRA-196Phase 1/2Gene therapy / editingSERPINA1not yet gradedNo reviewed efficacy summary in this indication
WVE-006Phase 1/2RNA / oligonucleotideSERPINA1 Z-allele mRNA (ADAR-mediated editing)not yet gradedNo reviewed efficacy summary in this indication
Efdoralprin Alfa
—(overall)
Protein / enzyme therapeuticAlpha-1 antitrypsin (AAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.